YPEL3 inhibitors are chemical compounds designed to target and inhibit the activity of the YPEL3 protein, which is part of the YPEL (Yippee-like) family of evolutionarily conserved proteins. YPEL3 is known to play a role in cellular processes such as cell growth regulation and differentiation, particularly in the context of cell cycle control. The YPEL family members, including YPEL3, have been found to possess conserved domains that suggest roles in various molecular pathways associated with cellular proliferation and structural integrity. YPEL3, in particular, is involved in promoting cell cycle arrest in certain contexts, and its inhibition can affect how cells progress through different stages of growth and division. It is thought to act as a modulator of signaling pathways that contribute to the regulation of cellular proliferation and the maintenance of homeostasis.
Inhibitors of YPEL3 work by disrupting the protein's function, leading to interference in the pathways where YPEL3 is actively involved. These inhibitors typically function by binding to specific regions of the YPEL3 protein, thus blocking its ability to interact with other molecular partners or execute its biological functions. This disruption can have downstream effects on the regulation of gene expression and protein synthesis, particularly those involved in the cell cycle. Since YPEL3 plays a key role in controlling cellular growth and differentiation, its inhibition could potentially lead to changes in the way cells respond to growth signals or environmental stressors. The detailed study of YPEL3 inhibitors provides insights into their structural features, mechanisms of action, and the broader implications of modulating YPEL3 activity at a molecular level, particularly regarding how it influences complex intracellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, reducing AKT phosphorylation which is upstream of YPEL3, leading to decreased YPEL3 stabilization. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor that prevents ERK pathway activation, subsequently downregulating YPEL3 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor, altering the stress response pathway that can control YPEL3 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, modifying the AP-1 transcription factor activity, which regulates YPEL3 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that affects YPEL3 by altering the protein synthesis machinery and potentially its expression levels. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor that can increase cellular levels of ubiquitinated proteins, indirectly influencing YPEL3 degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can stabilize proteins targeted for degradation, affecting YPEL3 turnover. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, which is involved in the ERK pathway, leading to reduced transcription of YPEL3. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor that impedes AKT activation, thereby influencing YPEL3's stabilization and function. | ||||||
IKK 16 | 1186195-62-9 | sc-204009 sc-204009A | 10 mg 50 mg | $219.00 $924.00 | 2 | |
Inhibits NF-κB activation, which can modulate YPEL3 expression by affecting transcription. | ||||||